DCB is a second generation irreversible EGFR TKIs that overcomes the disadvantages of the acquired resistance first line EGFR TKIs.13–15 When compared with gefitinib, DCB improved progression-free survival in the management of patients with positive EGFR mutation NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.